Spasticity, following the neurological disorder of cerebral palsy (CP), describes a
pathological condition, the central feature of which is involuntary and prolonged muscle …

Spasticity, following the neurological disorder of cerebral palsy (CP), describes a
pathological condition, the central feature of which is involuntary and prolonged muscle …

Botulinum toxin type A (BTXA) has been used for over 25 years in the management of
pediatric lower and upper limb hypertonia, with the first reports in 1993. The most common …

Aim To assess the efficacy and safety of repeat abobotulinumtoxinA injections in reducing
upper limb spasticity in children with cerebral palsy (CP). Method This was a double‐blind …

Gait deficits in cerebral palsy (CP) are often treated with a single-event multi-level surgery
(SEMLS). Selecting the treatment options (combination of bony and soft tissue corrections) …

Background: Cerebral palsy (CP) is the most common cause of childhood disability globally.
Botulinum toxin A injections are widely used to manage limb spasticity in children with CP …

BACKGROUND: In the United States, many children with cerebral palsy (CP) obtain health
care coverage through managed Medicaid, but little is known about the current …

Background Botulinum toxin (BTX) injection alone is not sufficient to treat spasticity in
children, notably those with cerebral palsy; thus, there is an emerging trend for adjunct …

Background To provide effective interventions for spasticity, accurate and reliable spasticity
assessment is essential. For the assessment, the Modified Tardieu Scale (MTS) has been …

BACKGROUND: Spasticity is common in cerebral palsy and can result in pain and
diminished health-related quality of life. OBJECTIVE: To evaluate the safety and efficacy of …